• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DIBI,一种具有增强抗菌活性的3-羟基吡啶-4-酮螯合铁结合聚合物。

DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity.

作者信息

Ang M Trisha C, Gumbau-Brisa Roger, Allan David S, McDonald Robert, Ferguson Michael J, Holbein Bruce E, Bierenstiel Matthias

机构信息

Chelation Partners Inc. , 1411 Oxford St. Suite 369 , Halifax , Nova Scotia B3H 3Z1 , Canada.

Department of Chemistry , Cape Breton University , 1250 Grand Lake Rd , Sydney , Nova Scotia B1P 6L2 , Canada . Email:

出版信息

Medchemcomm. 2018 Jun 18;9(7):1206-1212. doi: 10.1039/c8md00192h. eCollection 2018 Jul 1.

DOI:10.1039/c8md00192h
PMID:30109009
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6071711/
Abstract

Depriving microorganisms of bioavailable iron is a promising strategy for new anti-infective agents. The new, highly water-soluble, low molecular weight co-polymer DIBI was developed to selectively bind iron(iii) ions as a tris chelate and acts as a standalone anti-infective. Minimum inhibitory concentration (MIC) studies show DIBI is effective against representative reference strains for Gram-positive and Gram-negative bacteria and , and the fungus . Compared to the small molecule iron chelators, deferiprone and deferoxamine, DIBI outclassed these by factors of 100 to 1000 for inhibition of initial growth. DIBI and a series of related co-polymers ( of 2-9 kDa) were synthesized reversible addition-fragmentation chain transfer (RAFT) polymerization of a chelating 3-hydroxypyridin-4-one (HPO) methacrylamide monomer and -vinylpyrrolidone (NVP). Full incorporation of the HPO monomer into the co-polymers from the reaction solution was determined by H NMR spectroscopy and ranged from 4.6 to 25.6 mol%. UV-vis spectroscopy showed that all the HPO in DIBI binds readily to iron(iii) in a tris chelate mode to the maximum theoretical iron(iii) binding capacity of the co-polymer. Chemical characterization including single crystal X-ray diffraction analyses of the -benzyl protected and the functional HPO monomer are discussed. By design, DIBI is highly water soluble; the highest mass fraction in water tested was 70% w/w, without the need of organic co-solvents.

摘要

剥夺微生物可利用的铁是开发新型抗感染药物的一种有前景的策略。新型、高水溶性、低分子量共聚物DIBI被开发用于选择性地以三齿螯合物形式结合铁(III)离子,并作为一种独立的抗感染剂发挥作用。最低抑菌浓度(MIC)研究表明,DIBI对革兰氏阳性菌、革兰氏阴性菌以及真菌的代表性参考菌株均有效。与小分子铁螯合剂去铁酮和去铁胺相比,DIBI在抑制初始生长方面比它们高出100至1000倍。DIBI和一系列相关共聚物(2 - 9 kDa)是通过螯合3 - 羟基吡啶 - 4 - 酮(HPO)甲基丙烯酰胺单体和N - 乙烯基吡咯烷酮(NVP)的可逆加成 - 断裂链转移(RAFT)聚合反应合成的。通过1H NMR光谱法确定了HPO单体从反应溶液中完全掺入共聚物中,其范围为4.6至25.6摩尔%。紫外 - 可见光谱表明,DIBI中所有的HPO都以三齿螯合模式容易地与铁(III)结合,达到共聚物的最大理论铁(III)结合能力。讨论了包括苄基保护的和功能性HPO单体的单晶X射线衍射分析在内的化学表征。通过设计,DIBI具有高度水溶性;测试的水中最高质量分数为70%w / w,无需有机共溶剂。

相似文献

1
DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity.DIBI,一种具有增强抗菌活性的3-羟基吡啶-4-酮螯合铁结合聚合物。
Medchemcomm. 2018 Jun 18;9(7):1206-1212. doi: 10.1039/c8md00192h. eCollection 2018 Jul 1.
2
Enhanced Fe binding through cooperativity of 3-hydroxypyridin-4-one groups within a linear co-polymer: wrapping effect leading to superior antimicrobial activity.通过线性共聚物中3-羟基吡啶-4-酮基团的协同作用增强铁结合:包裹效应导致卓越的抗菌活性。
Biometals. 2020 Dec;33(6):339-351. doi: 10.1007/s10534-020-00253-1. Epub 2020 Oct 19.
3
DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage.DIBI,一种新型 3-羟基吡啶-4-酮螯合铁结合聚合物,通过促进 S 期 DNA 损伤来抑制乳腺癌细胞生长并作为化疗增敏剂发挥作用。
Biometals. 2019 Dec;32(6):909-921. doi: 10.1007/s10534-019-00222-3. Epub 2019 Oct 17.
4
Novel Iron-Chelator DIBI Inhibits Growth, Suppresses Experimental MRSA Infection in Mice and Enhances the Activities of Diverse Antibiotics .新型铁螯合剂DIBI抑制生长,抑制小鼠实验性耐甲氧西林金黄色葡萄球菌感染并增强多种抗生素的活性。
Front Microbiol. 2018 Aug 14;9:1811. doi: 10.3389/fmicb.2018.01811. eCollection 2018.
5
Antibiotic-Resistant Is Susceptible to the Novel Iron-Sequestering Anti-infective DIBI and in Experimental Pneumonia in Mice.耐抗生素的 易受新型铁螯合抗感染药物 DIBI 的影响,并在小鼠实验性肺炎中。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00855-19. Print 2019 Sep.
6
Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles and in a Murine Model of Experimental Vaginitis.新型螯合剂 DIBI 对白色念珠菌临床分离株的铁限制作用抑制其生长,并增加其对唑类药物的敏感性,并在实验性阴道炎的小鼠模型中。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.02576-17. Print 2018 Aug.
7
Inhibitory effect of iron withdrawal by chelation on the growth of human and murine mammary carcinoma and fibrosarcoma cells.螯合作用去除铁对人及小鼠乳腺癌和纤维肉瘤细胞生长的抑制作用。
Exp Mol Pathol. 2015 Oct;99(2):262-70. doi: 10.1016/j.yexmp.2015.07.008. Epub 2015 Jul 22.
8
Iron Withdrawal with DIBI, a Novel 3-Hydroxypyridin-4-One Chelator Iron-Binding Polymer, Attenuates Macrophage Inflammatory Responses.使用新型3-羟基吡啶-4-酮螯合铁聚合物DIBI进行铁去除可减轻巨噬细胞炎症反应。
Adv Pharm Bull. 2023 Mar;13(2):368-377. doi: 10.34172/apb.2023.040. Epub 2022 Jan 2.
9
Antimicrobial Activity of the Iron-Chelator, DIBI, against Multidrug-Resistant Canine Methicillin-Susceptible : A Preliminary Study of Four Clinical Strains.铁螯合剂DIBI对犬耐多药甲氧西林敏感菌的抗菌活性:四株临床菌株的初步研究
Pathogens. 2022 Jun 7;11(6):656. doi: 10.3390/pathogens11060656.
10
Anti-inflammatory effects of a novel iron chelator, DIBI, in experimental sepsis.新型铁螯合剂DIBI在实验性脓毒症中的抗炎作用
Clin Hemorheol Microcirc. 2017;67(3-4):241-250. doi: 10.3233/CH-179205.

引用本文的文献

1
Interactions Between Iron Metabolism and the Endocannabinoid System in Bacterial Infections.细菌感染中铁代谢与内源性大麻素系统之间的相互作用
Antibiotics (Basel). 2025 Jun 18;14(6):614. doi: 10.3390/antibiotics14060614.
2
Methicillin-resistant Staphylococcus pseudintermedius: epidemiological changes, antibiotic resistance, and alternative therapeutic strategies.耐甲氧西林中间葡萄球菌:流行病学变化、抗生素耐药性和替代治疗策略。
Vet Res Commun. 2024 Dec;48(6):3505-3515. doi: 10.1007/s11259-024-10508-8. Epub 2024 Aug 21.
3
The Hydroxypyridinone Iron Chelator DIBI Reduces Bacterial Load and Inflammation in Experimental Lung Infection.羟基吡啶酮铁螯合剂DIBI可降低实验性肺部感染中的细菌载量并减轻炎症。
Biomedicines. 2024 Jun 29;12(7):1452. doi: 10.3390/biomedicines12071452.
4
Iron Chelation as a Potential Therapeutic Approach in Acute Lung Injury.铁螯合作为急性肺损伤的一种潜在治疗方法
Life (Basel). 2023 Jul 30;13(8):1659. doi: 10.3390/life13081659.
5
Iron Withdrawal with DIBI, a Novel 3-Hydroxypyridin-4-One Chelator Iron-Binding Polymer, Attenuates Macrophage Inflammatory Responses.使用新型3-羟基吡啶-4-酮螯合铁聚合物DIBI进行铁去除可减轻巨噬细胞炎症反应。
Adv Pharm Bull. 2023 Mar;13(2):368-377. doi: 10.34172/apb.2023.040. Epub 2022 Jan 2.
6
Nutrient Limitation Sensitizes to Vancomycin.营养限制使 对万古霉素敏感。
ACS Infect Dis. 2023 Jul 14;9(7):1408-1423. doi: 10.1021/acsinfecdis.3c00167. Epub 2023 Jun 6.
7
Iron Acquisition and Metabolism as a Promising Target for Antimicrobials (Bottlenecks and Opportunities): Where Do We Stand?铁的获取和代谢作为抗菌药物的有前途的靶点(瓶颈和机遇):我们处于什么位置?
Int J Mol Sci. 2023 Mar 24;24(7):6181. doi: 10.3390/ijms24076181.
8
Iron Chelator DIBI Suppresses Formation of Ciprofloxacin-Induced Antibiotic Resistance in .铁螯合剂DIBI抑制环丙沙星诱导的抗生素耐药性的形成 。(你提供的原文似乎不完整,缺少具体针对哪种细菌或其他主体的信息)
Antibiotics (Basel). 2022 Nov 17;11(11):1642. doi: 10.3390/antibiotics11111642.
9
Antimicrobial Activity of the Iron-Chelator, DIBI, against Multidrug-Resistant Canine Methicillin-Susceptible : A Preliminary Study of Four Clinical Strains.铁螯合剂DIBI对犬耐多药甲氧西林敏感菌的抗菌活性:四株临床菌株的初步研究
Pathogens. 2022 Jun 7;11(6):656. doi: 10.3390/pathogens11060656.
10
Hydroxypyridinone-Based Metal Chelators towards Ecotoxicity: Remediation and Biological Mechanisms.基于羟基吡啶酮的金属螯合剂的生态毒性:修复及生物机制。
Molecules. 2022 Mar 18;27(6):1966. doi: 10.3390/molecules27061966.

本文引用的文献

1
Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.一种聚阳离子杯[4]芳烃衍生物单独及与抗生素联合使用的设计、合成与抗菌评价
Medchemcomm. 2017 Dec 1;9(1):160-164. doi: 10.1039/c7md00527j. eCollection 2018 Jan 1.
2
DIBI, a polymeric hydroxypyridinone iron chelator, reduces ocular inflammation in local and systemic endotoxin-induced uveitis.DIBI是一种聚合羟基吡啶酮铁螯合剂,可减轻局部和全身内毒素诱导的葡萄膜炎中的眼部炎症。
Clin Hemorheol Microcirc. 2018;69(1-2):153-164. doi: 10.3233/CH-189109.
3
Anti-inflammatory effects of a novel iron chelator, DIBI, in experimental sepsis.新型铁螯合剂DIBI在实验性脓毒症中的抗炎作用
Clin Hemorheol Microcirc. 2017;67(3-4):241-250. doi: 10.3233/CH-179205.
4
What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.就耐药性和药效学原理而言,我们对正在研发的新型抗菌药物有何期待。
J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):113-132. doi: 10.1007/s10928-017-9506-4. Epub 2017 Feb 4.
5
Notes from the Field: Pan-Resistant New Delhi Metallo-Beta-Lactamase-Producing Klebsiella pneumoniae - Washoe County, Nevada, 2016.实地记录:产泛耐药新德里金属β-内酰胺酶的肺炎克雷伯菌——内华达州瓦肖县,2016年
MMWR Morb Mortal Wkly Rep. 2017 Jan 13;66(1):33. doi: 10.15585/mmwr.mm6601a7.
6
Escherichia coli Harboring mcr-1 and blaCTX-M on a Novel IncF Plasmid: First Report of mcr-1 in the United States.携带新型IncF质粒上mcr - 1和blaCTX - M的大肠杆菌:美国mcr - 1的首次报道
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4420-1. doi: 10.1128/AAC.01103-16. Print 2016 Jul.
7
Synthesis of novel Iron(III) chelators based on triaza macrocycle backbone and 1-hydroxy-2(H)-pyridin-2-one coordinating groups and their evaluation as antimicrobial agents.基于三氮杂大环骨架和1-羟基-2(H)-吡啶-2-酮配位基团的新型铁(III)螯合剂的合成及其作为抗菌剂的评价。
J Inorg Biochem. 2016 Jul;160:49-58. doi: 10.1016/j.jinorgbio.2016.04.018. Epub 2016 Apr 16.
8
Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?抗生素耐药性破解者:再利用药物能否填补抗生素发现的空白?
Nat Rev Drug Discov. 2015 Dec;14(12):821-32. doi: 10.1038/nrd4675. Epub 2015 Oct 23.
9
Anti-inflammatory and anti-bacterial effects of iron chelation in experimental sepsis.铁螯合在实验性脓毒症中的抗炎和抗菌作用
J Surg Res. 2016 Jan;200(1):266-73. doi: 10.1016/j.jss.2015.07.001. Epub 2015 Jul 8.
10
Polymeric nanocarriers for the treatment of systemic iron overload.用于治疗全身性铁过载的聚合物纳米载体。
Mol Cell Ther. 2015 Mar 24;3:3. doi: 10.1186/s40591-015-0039-1. eCollection 2015.